PMID- 36230990
OWN - NLM
STAT- MEDLINE
DCOM- 20221017
LR  - 20221130
IS  - 2073-4409 (Electronic)
IS  - 2073-4409 (Linking)
VI  - 11
IP  - 19
DP  - 2022 Sep 27
TI  - Dendritic Cells: The Long and Evolving Road towards Successful Targetability in 
      Cancer.
LID - 10.3390/cells11193028 [doi]
LID - 3028
AB  - Dendritic cells (DCs) are a unique myeloid cell lineage that play a central role 
      in the priming of the adaptive immune response. As such, they are an attractive 
      target for immune oncology based therapeutic approaches. However, targeting these 
      cells has proven challenging with many studies proving inconclusive or of no 
      benefit in a clinical trial setting. In this review, we highlight the known and 
      unknown about this rare but powerful immune cell. As technologies have expanded 
      our understanding of the complexity of DC development, subsets and response 
      features, we are now left to apply this knowledge to the design of new 
      therapeutic strategies in cancer. We propose that utilization of these 
      technologies through a multiomics approach will allow for an improved directed 
      targeting of DCs in a clinical trial setting. In addition, the DC research 
      community should consider a consensus on subset nomenclature to distinguish new 
      subsets from functional or phenotypic changes in response to their environment.
FAU - Marmonti, Enrica
AU  - Marmonti E
AD  - Department of Translational Molecular Pathology, University of Texas MD Anderson 
      Cancer Center, Houston, TX 77030, USA.
FAU - Oliva-Ramirez, Jacqueline
AU  - Oliva-Ramirez J
AUID- ORCID: 0000-0001-9334-2066
AD  - Department of Translational Molecular Pathology, University of Texas MD Anderson 
      Cancer Center, Houston, TX 77030, USA.
FAU - Haymaker, Cara
AU  - Haymaker C
AUID- ORCID: 0000-0002-1317-9287
AD  - Department of Translational Molecular Pathology, University of Texas MD Anderson 
      Cancer Center, Houston, TX 77030, USA.
LA  - eng
GR  - U24 CA224285/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20220927
PL  - Switzerland
TA  - Cells
JT  - Cells
JID - 101600052
SB  - IM
MH  - Adaptive Immunity
MH  - Cell Lineage
MH  - Clinical Trials as Topic
MH  - *Dendritic Cells
MH  - Humans
MH  - Myeloid Cells
MH  - *Neoplasms/therapy
PMC - PMC9563837
OTO - NOTNLM
OT  - antigen-presenting cells
OT  - cancer
OT  - dendritic cells
OT  - immunotherapy
OT  - monocytes
COIS- C.H. reports speaker’s fees from the Society for Immunotherapy of Cancer, 
      serves as an advisory board member for Briacell and the Mesothelioma Applied 
      Research Foundation, has received personal fees from Nanobiotix and receives 
      funding to the MD Anderson Cancer Center from Iovance, Sanofi, Dragonfly 
      Therapeutics, and BTG outside the submitted work. The other authors have nothing 
      to disclose.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/18 06:00
PMCR- 2022/09/27
CRDT- 2022/10/14 01:54
PHST- 2022/08/10 00:00 [received]
PHST- 2022/09/19 00:00 [revised]
PHST- 2022/09/22 00:00 [accepted]
PHST- 2022/10/14 01:54 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/18 06:00 [medline]
PHST- 2022/09/27 00:00 [pmc-release]
AID - cells11193028 [pii]
AID - cells-11-03028 [pii]
AID - 10.3390/cells11193028 [doi]
PST - epublish
SO  - Cells. 2022 Sep 27;11(19):3028. doi: 10.3390/cells11193028.